Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Analyst Ratings
Moderate Buy
4 Buy
8 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
FATE Stock 12 Month Forecast
Average Price Target
$6.17
▲(370.99% Upside)
| Highest Price Target$12.00 | Average Price Target$6.17 | Lowest Price Target$2.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
03/07/25
Morgan Stanley
Reiterated
03/06/25
Stifel Nicolaus
Reiterated
03/06/25
Piper Sandler
Reiterated
03/06/25
Leerink Partners
$12
Buy
816.03%
Upside
Reiterated
03/06/25
Optimistic Outlook for Fate Therapeutics' FT819 in Cell-Therapy Space Amid Promising Phase 1 Results
Oppenheimer
―
Hold
―
Reiterated
03/06/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (NASDAQ: FATE) and Stevanato Group (NYSE: STVN)
Robert W. Baird
$5
Hold
281.68%
Upside
Reiterated
11/13/24
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Fate Therapeutics (NASDAQ: FATE)
H.C. Wainwright
$5
Hold
281.68%
Upside
Reiterated
08/22/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Fate Therapeutics (NASDAQ: FATE)
Citi
$10
Buy
663.36%
Upside
Reiterated
05/15/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), Acumen Pharmaceuticals (NASDAQ: ABOS) and DENTSPLY SIRONA (NASDAQ: XRAY)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
03/07/25
Morgan Stanley
Reiterated
03/06/25
Stifel Nicolaus
Reiterated
03/06/25
Piper Sandler
Reiterated
03/06/25
Leerink Partners
$12
Buy
816.03%
Upside
Reiterated
03/06/25
Optimistic Outlook for Fate Therapeutics' FT819 in Cell-Therapy Space Amid Promising Phase 1 Results
Oppenheimer
―
Hold
―
Reiterated
03/06/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (NASDAQ: FATE) and Stevanato Group (NYSE: STVN)
Robert W. Baird
$5
Hold
281.68%
Upside
Reiterated
11/13/24
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Fate Therapeutics (NASDAQ: FATE)
H.C. Wainwright
$5
Hold
281.68%
Upside
Reiterated
08/22/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Fate Therapeutics (NASDAQ: FATE)
Citi
$10
Buy
663.36%
Upside
Reiterated
05/15/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), Acumen Pharmaceuticals (NASDAQ: ABOS) and DENTSPLY SIRONA (NASDAQ: XRAY)
Best Analysts Covering Fate Therapeutics
Which Analyst Should I Follow If I Want to Buy FATE and Sell After:
1 Month
xxx
Success Rate
10/28 ratings generated profit
Average Return
-4.19%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.71% of your transactions generating a profit, with an average return of -4.19% per trade.
3 Months
xxx
Success Rate
12/28 ratings generated profit
Average Return
-0.48%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -0.48% per trade.
1 Year
Success Rate
5/17 ratings generated profit
Average Return
-19.27%
reiterated a buy rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -19.27% per trade.
2 Years
xxx
Success Rate
3/17 ratings generated profit
Average Return
-52.12%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 17.65% of your transactions generating a profit, with an average return of -52.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
FATE Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
6
7
6
4
6
Buy
3
3
2
0
0
Hold
21
23
14
2
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
33
22
6
15
Each month's total comprises the sum of three months' worth of ratings.
FATE Financial Forecast
FATE Stock Forecast FAQ
What is FATE’s average 12-month price target, according to analysts?
Based on analyst ratings, Fate Therapeutics’s 12-month average price target is 6.17.
What is FATE’s upside potential, based on the analysts’ average price target?
Fate Therapeutics has 370.99% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is FATE a Buy, Sell or Hold?
Fate Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 8 hold ratings and 0 sell ratings.
What is Fate Therapeutics’s price target?
The average price target for Fate Therapeutics is 6.17. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $2.50. The average price target represents 370.99% Increase from the current price of $1.31.
The highest analyst price target is $12.00 ,the lowest forecast is $2.50. The average price target represents 370.99% Increase from the current price of $1.31.
What do analysts say about Fate Therapeutics?
Fate Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of FATE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.